RPG
SGMO

Risk Paradigm Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Risk Paradigm Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-115
Closed -$649 – 349
2015
Q3 		$649 Buy
+115
New +$948 ﹤0.01% 407

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Risk Paradigm Group's SGMO Position: Q4 2015 in Review

Risk Paradigm Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2015, closing a stake of 115 shares — an estimated $649 sold.

Risk Paradigm Group first reported a position in SGMO in Q3 2015 and held it in 1 quarter. The position peaked at $649 in Q3 2015. 141 funds tracked by Wall St. Rank hold SGMO as of Q4 2015.

  • Risk Paradigm Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2015 after selling out during the quarter.
  • Risk Paradigm Group sold 115 SANGAMO THERAPEUTICS INC shares in Q4 2015, an estimated $649.
  • Risk Paradigm Group first reported a position in SANGAMO THERAPEUTICS INC in Q3 2015 and held it in 1 quarter.
  • Risk Paradigm Group's SANGAMO THERAPEUTICS INC position peaked at $649 in Q3 2015.
  • 141 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2015.

Based on Risk Paradigm Group's 13F filing for Q4 2015, filed 10 Feb 2016.